Summary & Overview
HCPCS J9061: Injection, amivantamab-vmjw, 2 mg
HCPCS Level II code J9061 designates a 2 mg unit of amivantamab-vmjw, an intravenously administered monoclonal antibody used in oncology care. This code is used when billing for the drug supply of amivantamab-vmjw and matters nationally because high-cost oncology biologics account for substantial outpatient drug spending and require precise coding for coverage, prior authorization, and reimbursement. Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find benchmarks for how this HCPCS Level II code is commonly billed, the clinical context for use as an injectable biologic therapy in outpatient infusion and oncology settings, and a summary of payer coverage considerations and policy updates that typically affect biologic oncology drugs. The publication highlights coding nuances relevant to billing the injectable supply, common billing pathways across major payers, and areas where prior authorization and medical necessity policies frequently apply. Data not available in the input is noted where specific payer coverage rules, exact reimbursement rates, and associated ICD-10 diagnoses would normally be provided.
Billing Code Overview
HCPCS Level II code J9061 represents Injection, amivantamab-vmjw, 2 mg. This code denotes a billed unit of the monoclonal antibody therapy amivantamab-vmjw supplied for intravenous administration. The service type is injectable biologic therapy intended for administration by a clinician.
The typical site of service for this therapy is outpatient infusion centers, hospital outpatient departments, and oncology clinics where intravenous biologic agents are administered under clinical supervision.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic or unresectable non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation who is scheduled to receive intravenous infusion of J9061 (amivantamab-vmjw) in an outpatient oncology infusion clinic or hospital outpatient infusion center. The workflow begins with oncologist evaluation and documentation of molecular testing confirming an EGFR exon 20 insertion. Pre-treatment orders include verification of baseline labs (CBC, CMP), documentation of weight for dose calculation, infusion consent, and allergy history. A pharmacy prepares the J9061 dose in a biologics-safe environment and labels the syringe or bag per institutional policy. Nursing performs pre-infusion vital signs, places an IV access, and administers premedications as ordered (e.g., antihistamine, acetaminophen, corticosteroid) to reduce infusion-related reactions. The infusion is administered per manufacturer and institutional protocols with continuous monitoring for infusion reactions; vital signs are recorded at regular intervals and the patient is observed for a required period after completion. Any acute reactions are managed per protocol and documented. Post-infusion orders include scheduling the next infusion, documenting dose, lot number, and any modifiers applicable to billing, and updating the patient’s electronic health record with infusion time, total milligrams administered (units billed as J9061 per 2 mg), and any adverse events. Typical sites of service are outpatient oncology infusion clinics, hospital outpatient departments, and, when clinically appropriate, physician office-based infusion suites. Patient scenario modifiers that may apply include circumstances such as therapy initiated in observation status, participation in an approved limited distribution program, or partial administration due to an infusion reaction.